

Affinity Sensors

[View the current Affinity Sensors Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/223-Affinity+Sensors.html)

(<http://www.bioportfolio.com/biocorporate/223-Affinity+Sensors.html>)

Contact Details:

**Saxon Way Bar Hill
Cambridge
Cambridgeshire
CB3 8SL
United Kingdom**

Tel: 44 1954 789976
Fax: 44 1954 789417
Email:

Affinity Sensors is a division of the Thermo BioAnalysis Corporation. Thermo BioAnalysis designs, manufactures and markets instruments and information management systems for use in biochemical research and production, as well as in clinical diagnostics. Other divisions in the group include Thermo CE, specialising in capillary electrophoresis; Thermo BioAnalysis Ltd, specialising in MALDI-TOF (Matrix Assisted Laser Desorption/Ionisation Time-of-Flight mass spectrometry); Eberline (health physics instrumentation); Dynex Technologies (Microtiter technology); and LabSystems (LIMS and chromatography data systems); and from Life Sciences International, Hybaid (DNA thermal cyclers and consumables) and Labsystems (microplate based instruments and liquid handling equipment).

Thermo BioAnalysis is a public corporation which is majority owned by Thermo Electron, and together with its parent company Thermo Instrument Systems, is the world's largest analytical instrument company.

Recent Publications by Affinity Sensors:



- [Analysis of calibration methodologies for solvent effects in drug discovery studies using evanescent wave biosensors.](#)
*Recent improvements in sensitivity have enabled direct binding studies of...*6th March, 2008
Affinity Sensors, Saxon Way, Bar Hill, Cambridge, UK.- Biosens Bioelectron. 2005 Jul 15;21(1):128-34. ([DOI Direct Link](#))
- [New approaches for the analysis of molecular recognition using the IAsys evanescent wave biosensor.](#)
*Trends in the analysis of molecular recognition using the IAsys evanescent...*20th June, 2000
Affinity Sensors, Cambridge, UK.- J Mol Recognit. 1998 Winter;11(1-6):194-9. ([DOI Direct Link](#))
- [Ligand loading at the surface of an optical biosensor and its effect upon the kinetics of protein-protein interactions.](#)
*Optical biosensors are finding increasing use in the determination of...*20th June, 2000

Press Releases on Affinity Sensors:

<p>YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA</p>	<p>23rd November, 2009</p>	<p>YM BioSciences Inc.</p>	<p>MISSISSAUGA, ON, Nov. 23 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of</p>
<p>YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING</p>	<p>18th November, 2009</p>	<p>YM BioSciences Inc.</p>	<p>MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of</p>
<p>Reportlinker Adds Biotechnology Reagents - A Global Market Perspective</p>	<p>18th November, 2009</p>	<p>Reportlinker</p>	<p>NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Biotechnology Reagents - A Global Market Perspective http://www</p>
<p>YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEETING</p>	<p>17th November, 2009</p>	<p>YM BioSciences Inc.</p>	<p>MISSISSAUGA, ON, Nov. 17 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of</p>
<p>Anthem Blue Cross and Blue Shield Adds Affinity Health System to Provider Network</p>	<p>16th November, 2009</p>	<p>Anthem Blue Cross Blue Shield in Wisconsin</p>	<p>MILWAUKEE and MENASHA, Wis., Nov. 16 /PRNewswire/ -- Anthem Blue Cross and Blue Shield (Anthem) and Affinity Health System (Affinity) announced today a new agreement that will allow Anthem members in</p>

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

